Core Viewpoint - The Chinese pharmaceutical industry is experiencing a significant transformation, moving from a focus on generic drugs to global innovation, driven by an increase in business development (BD) activities and the emergence of the NewCo model [1][2][5]. Group 1: Market Performance - The Hang Seng Index opened up by 0.74% and the Hang Seng Tech Index by 0.97% on June 5, 2025, indicating positive market sentiment [1]. - The Hang Seng Healthcare ETF (513060) saw a more than 1% increase in intraday trading, with a trading volume exceeding 500 million yuan and a turnover rate of over 6% [1]. - Year-to-date, the Hang Seng Healthcare ETF has risen nearly 40%, reflecting strong market interest [1]. Group 2: Business Development Trends - Since 2024, there has been a notable increase in the volume and value of outbound BD transactions for Chinese innovative drugs, with significant deals in areas such as ADCs, bispecific antibodies, and GLP-1 assets [2]. - The total value of License-out transactions in the innovative drug sector has surged from approximately $11 billion in 2020 to over $51 billion in the first ten months of 2024, showcasing a substantial growth trend [2]. - The increase in transaction size and number is attributed to upgraded transaction structures, enhanced international recognition, and innovative business models like the NewCo model [2]. Group 3: NewCo Model Advantages - The NewCo model addresses challenges such as financing difficulties, monetization issues, and high R&D risks by creating independent companies through partnerships between domestic biotech firms and foreign investors [3][4]. - This model allows for increased financing and monetization channels, enabling independent fundraising while retaining traditional License-out revenue [3]. - It also reduces R&D and commercialization risks by outsourcing high-cost clinical development and market promotion to the NewCo or partners [4]. Group 4: Future Outlook - The pharmaceutical sector is poised for positive development, having completed a transition from old to new growth drivers, with a focus on innovation over generics [5]. - Companies like Heng Rui, Han Sen, and Ke Lun have successfully transformed into innovative players, while outbound capabilities continue to improve [5]. - The rise of AI in healthcare is expected to unlock new growth opportunities, with a recommendation to focus on innovative drugs, outbound strategies, and high-barrier industries [5].

Group 1: Virtual Assets and Financial Policies - Hong Kong's Financial Secretary, Xu Zhengyu, announced that the Hong Kong Securities and Futures Commission is considering introducing virtual asset derivatives trading for professional investors, aiming to enhance product options while ensuring orderly, transparent, and secure trading [2] - The Financial Secretary will release a second policy declaration on virtual assets, outlining future policy visions, including integrating traditional financial services with technological innovations in the virtual asset sector [2] - The government plans to optimize tax incentives for funds, single-family offices, and related equity transactions, including allowing virtual assets to qualify for tax relief [2] Group 2: Energy Sector Developments - The National Energy Administration is initiating pilot projects for the construction of a new power system, focusing on advanced directions and typical projects to explore new technologies and models [3] - The pilot projects will emphasize seven key areas, including grid technology, system-friendly renewable energy stations, smart microgrids, and virtual power plants [3] - The initiative encourages the adoption of new technologies and models while supporting projects that utilize national technology major special projects and energy technology equipment [3] Group 3: Technology and Industrial Development - The Ministry of Industry and Information Technology is focusing on promoting the development of the artificial intelligence industry and its integration into new industrialization [3] - The meeting emphasized strengthening computing power supply and enhancing the intelligence level of key product equipment [3] Group 4: Market Performance - In the U.S. stock market, major indices showed mixed results, with the Dow Jones down 0.22% and the Nasdaq up 0.32% [4] - Large technology stocks had varied performances, with notable gains in companies like Google (up 1.65%) and Meta (up 3.16%), while Apple and Tesla saw declines [5] - In the Hong Kong market, the Hang Seng Index rose 0.60%, with the technology index also showing an increase [6] Group 5: Company News - Zhixing Technology received a notification for providing front-view integrated machines based on its Journey 3 model for nine commercial vehicles from leading automakers [8] - Zoomlion Heavy Industry announced an investment of approximately 723 million yuan to acquire a 36% stake in Zoomlion Heavy Industry Financing Leasing (Beijing) [9] - Jieli Trading reported a user base of approximately 854,000, reflecting a year-on-year growth of 4.6% [10] - China Vanke reported a cumulative contract sales figure of 4.139 billion yuan for the first five months, a year-on-year decrease of 44.83% [11] - Agile Group reported cumulative contract sales of 4.24 billion yuan for the first five months [12] - CIFI Holdings received the necessary support from the majority of plan creditors during its planned meeting [13] - Hansoh Pharmaceutical's Amivantamab has been approved for market launch by the UK Medicines and Healthcare products Regulatory Agency [14]

Group 1 - The pharmaceutical and biotechnology index rose by 2.21%, outperforming the CSI 300 index by 3.30 percentage points and the ChiNext index by 2.00 percentage points, ranking second among 31 sub-industries [3] - Recent IND applications have been initiated for drugs such as BG-60366 from BeiGene and RFUS-949 from Renfu Pharmaceutical, while clinical applications for BGB-C354 and SSS55 injection have also been newly undertaken [4] Group 2 - The upcoming 2025 ASCO conference is expected to showcase Chinese innovative pharmaceutical companies, with a notable global licensing deal of $6.05 billion between 3SBio and Pfizer, enhancing the focus on PD-1 (PD-L1)/VEGF dual antibody products [5] - There are currently 14 PD-1 (PD-L1)/VEGF products in clinical stages globally, all associated with Chinese companies, with the fastest progress seen in the drug Ivorisumab from CanSino Biologics, which has been approved in China [5] Group 3 - Companies such as Zhenzhen Cell, Rongchang Biopharmaceutical, Junshi Biosciences, and Huahai Pharmaceutical have clinical products progressing quickly but have not yet established business development partnerships [6] - Huahai Pharmaceutical's HB0025 for endometrial cancer is expected to start Phase III clinical trials in the second half of 2025, while Zhenzhen Cell's SCTB14 has initiated Phase II/III clinical trials in March 2025 [6] Group 4 - The investment strategy for 2025 emphasizes structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: in-hospital payments, out-of-pocket payments, and overseas payments [7] - The strategy highlights three key directions: policy support for innovative drugs and devices, expanding public demand for blood products and home medical devices, and the upward cycle of overseas sales for products like heparin and respiratory-related treatments [7]

Core Viewpoint - Hansoh Pharmaceutical's innovative drug, Amivantamab (Aumseqa®), has been approved for marketing in the UK, marking it as the first innovative drug from the company to enter the overseas market and the first Chinese-origin EGFR-TKI to be launched internationally [1][2]. Group 1: Drug Approval and Market Entry - Amivantamab is approved for use as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activated EGFR mutations, as well as for patients with T790M mutation-positive NSCLC [1]. - The drug has already been approved for four indications in China, making it the most approved indication for a Chinese-origin third-generation EGFR-TKI [2]. Group 2: Market Context and Competitors - As of March 2025, there are seven third-generation EGFR-TKI products available in China, including Amivantamab and others like Osimertinib and Furmonertinib [3]. - The market for NSCLC treatments is significant, with lung cancer accounting for 18.7% of global cancer deaths in 2022, and NSCLC being the most common type, representing approximately 85% of all lung cancer cases [4]. Group 3: Historical Context and Future Prospects - The first-generation EGFR-TKI, Gefitinib, was launched in the early 2000s, followed by second-generation drugs that also faced resistance issues, leading to the development of third-generation EGFR-TKIs like Osimertinib [5]. - Current research is focused on addressing resistance issues associated with third-generation EGFR-TKIs, with innovations such as EGFR/C-MET dual antibodies and ADC drugs being explored [6].

Group 1: Market Reactions and Political Developments - The market anticipates favorable policies from the Lujiazui Forum, reflected in a 0.60% increase in the Hang Seng Index [1] - The election of Lee Jae-myung as South Korea's president led to a 2.66% rise in the KOSPI index, entering a technical bull market, with a target of 5000 points set by Lee [1] - Lee's political agenda includes promoting cryptocurrency ETF legalization and establishing a regulatory framework for stablecoins, benefiting companies like OSL Group [1] Group 2: Rare Earth Export Controls and Automotive Industry - China's rare earth export controls have raised concerns among global automakers about potential production delays, prompting urgent discussions for alternative solutions [2] - Jinli Permanent Magnet reported a 14.19% year-on-year revenue increase to 1.754 billion yuan and a 57.85% rise in net profit, with expectations of a 20-30% production increase this year [2] - Lithium resource stocks, including Longpan Technology and Tianqi Lithium, saw gains exceeding 4% [2] Group 3: Energy Sector Developments - Meta signed a 20-year contract with Constellation Energy to purchase nuclear power starting mid-2027, highlighting the shift towards low-carbon energy sources [3] - China General Nuclear Power's stock surged over 28% following a uranium sales agreement with its parent company, indicating strong market interest in nuclear energy [3] - Other green energy stocks, such as Shankai Holdings, also experienced significant gains [3] Group 4: Biotechnology and Clinical Research - Innovent Biologics presented promising Phase I clinical trial data for its dual-specific antibody IBI363 at the ASCO annual meeting, leading to a stock increase of over 14% [4] - Other biotech firms, including Junshi Biosciences and Innovent, reached annual highs, indicating strong investor interest in the sector [4] Group 5: Consumer Market Trends - TOPTOY, a trendy toy platform, is preparing for an IPO, capitalizing on the booming market for collectible toys [5] - Other consumer stocks, such as Mixue Group and Maogeping, also saw significant increases, reflecting a collective bullish sentiment in the consumer sector [5] - The new regulations on e-cigarette production in China are expected to enhance investor confidence in the industry, with related stocks like Smoore International rising over 13% [5] Group 6: Data Center Industry Insights - Neway Network Group is positioned to benefit from the doubling demand for data centers in the Asia-Pacific region, driven by AI and digital transformation [8] - The company is expanding its data center capacity significantly, with projects like MEGAIDC expected to enhance its operational capabilities [9][10] - The firm has established itself as a leading interconnection hub in Asia, with major clients including Amazon AWS and Alibaba [10]

Market Performance - As of June 4, 2025, the Shanghai Composite Index rose by 0.42% to 3376.20 points, while the Shenzhen Component Index increased by 0.87% to 10144.58 points, and the ChiNext Index climbed by 1.11% to 2024.93 points [1] - The total trading volume of both markets reached 1.15 trillion yuan, marking the fifth consecutive day of exceeding one trillion yuan [1] - The jewelry sector showed strong performance with a daily increase of 5.95%, followed by leisure food and personal care products, which rose by 4.45% and 3.37% respectively [1] ETF Performance - A total of 1049 non-currency ETFs in the market increased, with an increase ratio of 91% [1] - The Hang Seng Innovative Drug Index rose by 3.83%, with related ETFs also showing significant gains of 3.61% and 3.55% [1] - The latest share size of the Hang Seng Innovative Drug ETF (520500.SH) reached 366 million shares, closely tracking the performance of the Hang Seng Innovative Drug Index [3] Valuation Metrics - The latest P/E ratio (PE-TTM) for the Hang Seng Innovative Drug Index is 26.92, which is lower than the average of over 11.03% in the past three years [4] - The P/E ratio for the Hang Seng Hong Kong Stock Connect Innovative Drug Index stands at 26.64, also below the average of over 12.16% in the last three years [5] - The National Certificate Hong Kong Stock Connect Innovative Drug Index has a P/E ratio of 29.36, lower than the average of over 10.84% in the past three years [5] Declining ETFs - A total of 71 non-currency ETFs declined, with a decrease ratio of 6% [5] - The top declining ETFs included the Greater Bay Area ETF, which fell by 1.41%, and the Transportation ETF, which decreased by 0.82% [7] Premium Rates - The S&P 500 Consumer Select Index showed a premium of 24.67%, while the S&P 500 Index had a premium of 17.11% [8] - The top ETFs by premium rate included the S&P Consumer ETF (24.67%) and the S&P 500 ETF (17.11%) [10]

Core Insights - The collaboration between Hansoh Pharmaceutical and Regeneron involves a deal worth over $2 billion, including an $80 million upfront payment and potential milestone payments of up to $1.93 billion, along with double-digit royalties on future sales [2][9][16] Group 1: HS-20094 Drug Overview - HS-20094 is an innovative GLP-1/GIP dual receptor agonist that has shown promising efficacy and safety data in multiple Phase II clinical trials [3][5] - The drug works by selectively activating GLP-1 and GIP receptors, promoting insulin secretion, delaying gastric emptying, and suppressing appetite, leading to improved glycemic control and weight loss [3][5] - The administration method is a once-weekly subcutaneous injection, enhancing patient convenience [3][4] Group 2: Clinical Trial Progress - In a Phase II study, HS-20094 demonstrated significant reductions in HbA1c levels compared to baseline, with reductions of -0.63%, -0.75%, and -0.84% for the 5mg, 10mg, and 15mg doses, respectively [5] - Weight loss was also observed in HS-20094 groups, with reductions of -1.27%, -2.51%, and -4.41%, showing a dose-dependent effect and outperforming the placebo group [5] - HS-20094 is currently undergoing Phase III clinical trials in China for obesity and Phase IIb trials for diabetes [5] Group 3: Strategic Importance for Companies - The partnership with Regeneron marks a significant strategic move for Hansoh Pharmaceutical, enhancing its global presence and financial returns while showcasing its R&D capabilities [9][11] - Regeneron aims to leverage HS-20094 to diversify its obesity treatment portfolio and explore combinations with its proprietary drugs to address obesity-related complications [6][7] Group 4: Market Context - The GLP-1R/GIPR agonist market is rapidly growing due to increasing obesity and diabetes rates, with only Eli Lilly's Mounjaro currently approved, generating sales of $16.4 billion in 2024 [12][13] - Domestic companies are quickly advancing in the GLP-1R/GIPR space, with several candidates in Phase III trials, including Hansoh's HS-20094 [12][14][15] Group 5: Financial Performance of Regeneron - Regeneron reported revenues of $647.07 million for the second quarter of 2024, with a net profit of $215.43 million, indicating strong financial health [8]

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [31]. Core Insights - The MSCI China Healthcare Index has increased by 27.6% since the beginning of 2025, outperforming the MSCI China Index by 14.5% [2]. - The international competitiveness of Chinese innovative drugs is being demonstrated through significant overseas licensing deals, reflecting a strong market presence [2]. - The report anticipates a valuation recovery in the pharmaceutical industry by 2025, driven by factors such as overseas licensing transactions, optimization of domestic procurement policies, and the implementation of new medical insurance categories [5]. Summary by Sections 1. **Industry Research - Medical Insurance Negotiations** - Continued support for innovation and recovery in overseas R&D demand [5]. 2. **Industry Research - Medical Equipment** - Expected recovery in bidding for medical devices and fruitful outcomes from innovative drug overseas transactions [5]. 3. **Industry Research - Medical Insurance Directory** - The results of adjustments to the medical insurance directory are expected to continuously support innovation [5]. 4. **Industry Research - Ongoing Policy Efforts** - Positive outlook for valuation rebound due to sustained policy support [5]. 5. **Industry Research - New Medical Insurance Categories** - The introduction of new medical insurance categories is expected to open up domestic payment space for innovative drugs [5]. 6. **Industry Research - Valuation Recovery** - The industry is poised for a valuation recovery, with several companies recommended for purchase [5]. 7. **Industry Research - Drug Pricing Policies** - Drug pricing policies are expected to be optimized, with accelerated commercialization of medical AI [5]. 8. **Industry Research - Anticipated Drug Procurement Policy Optimization** - Expectations for the implementation of an "innovative drug directory" [5]. 9. **Industry Research - 2024 Performance Review** - Innovative drugs are expected to dominate the market [5].

该基金核心持仓包括创新药企业恒瑞医药、百济神州、信达生物、科伦药业、中国生物制药、翰森制药 以及CXO的药明康德、凯莱英和泰格医药，是少数同时布局A股和港股创新药龙头的基金，也是跟踪该 指数的全市场独家产品。 未来以创新药为核心的医药科技股有望成为行情的焦点！当前医药行业估值处于过去10年中较低水平， 其刚需属性决定行业未来兼具成长性和确定性。布局创新药，可上支付宝搜索天弘恒生沪深港创新药50 指数（C类份额：014565，A类份额：014564）。如想布局ETF的投资者，创新药ETF天弘（代码： 517380）。市场有风险，投资需谨慎，所提及个股仅作展示，不作任何推荐。 天弘恒生沪深港创新药精选50指数布局较为完整的创新药产业链，覆盖临床前研究﹣临床研究﹣研发定 制生产﹣药品上市及商业化各环节，从机制上可进一步降低投资创新药企业本身存在的不确定性，获得 较好的收益风险特征和长期投资回报。 6月4日早盘，创新药再度走强。截至11:22，恒生沪深港创新药精选50指数涨超2.7%，成股份信达生物 涨13%，泰格医药、亚盛医药﹣B、科伦药业涨超3%。 消息面上，当地时间2025年5月30日至6月3日，2025年美国 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The PD-1 (PD-L1)/VEGF dual antibody concept is gaining significant attention, with Chinese innovative pharmaceutical companies leading the research and development efforts [2][20]. - The global market for dual antibodies is projected to exceed $80 billion by 2030, with PD-1 (PD-L1)/VEGF drugs expected to challenge traditional PD-1/PD-L1 therapies in cancer treatment [20][21]. - The report highlights the importance of clinical data barriers and international expansion for companies in this sector, suggesting that these factors will create differentiated investment opportunities [3][26]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 2.21%, outperforming the CSI 300 index by 3.30 percentage points [11][12]. - Among sub-industries, other biological products led with a 4.65% increase, while offline pharmacies saw a decline of 2.69% [12][19]. Clinical Progress - Notable advancements include the IND applications for BG-60366 by BeiGene and RFUS-949 by Renfu Pharmaceutical, as well as ongoing clinical trials for several drugs [29][30]. - Companies like Hengrui Medicine and Shijiazhuang Yiling Pharmaceutical are in Phase III trials, while others are in earlier stages [29][31]. Investment Strategy - The report emphasizes a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: hospital payments, out-of-pocket payments, and overseas payments [4][26]. - Key recommendations include Hengrui Medicine, Mindray Medical, United Imaging Healthcare, and Yuyue Medical [4]. Company Updates - Recent announcements include significant collaborations and product approvals, such as the $60.5 billion global licensing deal between 3SBio and Pfizer [2][28]. - The report notes that as of June 1, 2025, there are 14 PD-1 (PD-L1)/VEGF products in clinical stages, all associated with Chinese companies [21][24].